- The African Union (AU) aims to manufacture 60 percent of its own vaccines by 2040, a significant jump from the current 1 percent.
- The initiative, led by the Africa CDC, seeks to achieve sovereign health security, reduce dependence on imports, and mitigate supply chain vulnerabilities exposed during the COVID-19 pandemic.
- Challenges include securing high-risk financing, navigating intellectual property patents, and ensuring a predictable market demand for African-made products.
The Strategic Plan
- The Africa CDC established the Partnership for Africa Vaccine Manufacturing (PAVM), now renamed the Platform for Harmonised African Health Products Manufacturing (PHAHM), to coordinate the roadmap.
- The initiative addresses a critical gap: Africa accounts for 16 percent of the global population and 25 percent of the global disease burden but imports 99 percent of its vaccines.
- Demand for vaccines is projected to triple by 2040 as the population grows to 2 billion, with the AU prioritizing 22 diseases for local production, including tuberculosis, HIV, and various respiratory and viral illnesses.
Current Manufacturing Landscape
- Out of 574 health product manufacturers in Africa, current vaccine capabilities are limited:
- 40 percent focus on packaging and labeling.
- 40 percent perform "fill-and-finish" operations.
- Only five companies conduct drug substance manufacturing, mostly at a small scale.
- The Africa CDC identifies 25 active projects at various development stages, with three expected to secure WHO prequalification within five years.
Hurdles and Requirements
- Intellectual Property: Patents held by private firms complicate technology transfer.
- Infrastructure and Talent: Critics highlight the need to retain skilled scientists by improving local work environments and salaries.
- Policy and Cooperation: Success depends on leveraging the African Continental Free Trade Area (AfCFTA) to harmonize trade policies, eliminate market fragmentation, and secure member state commitments to buy locally-produced supplies.
- Funding: Despite billions in pledges from partners like the EU, the World Bank, and GAVI, sustainable financing remains a primary concern due to the high-risk nature of the industry.